<DOC>
	<DOCNO>NCT02876094</DOCNO>
	<brief_summary>Several factor make use celecoxib human SMA patient appeal include : 1 ) low-dosing require potential therapeutic effect ( correspond dose human much low commonly use adult child ; 2 ) favourable side effect profile drug ( particularly dosing require ) ; 3 ) fact celecoxib cross blood brain barrier 4 ) demonstration efficacy genetically pathophysiologically faithful animal mode . The investigator therefore believe celecoxib promising disease modify therapy SMA .</brief_summary>
	<brief_title>Effect Low-Dose Celecoxib SMN2 Patients With Spinal Muscular Atrophy</brief_title>
	<detailed_description>This pilot , open-label , dose-response study patient SMA type II III . All patient treat dose daily celecoxib ( 40 , 80 160 mcg/kg ) period two week , total 6 week ( 42 day ) treatment .</detailed_description>
	<mesh_term>Atrophy</mesh_term>
	<mesh_term>Muscular Atrophy , Spinal</mesh_term>
	<mesh_term>Muscular Atrophy</mesh_term>
	<mesh_term>Celecoxib</mesh_term>
	<criteria>1 . Confirmed genetic diagnosis consistent SMA include : SMN1 gene deletion , rearrangement and/or mutation 2 . Sufficient clinical information enable patient classify either SMA type II III . ( Patients SMA type II define achieve motor milestone sit independently &gt; 30 second able stand walk unsupported . Patients SMA type III define achieve motor milestone stand walk independently ) . 3 . Confirmed genetic test result indicate number SMN2 gene copy 4 . Age &gt; 2.0 year old screen 5 . Patients weigh least 12 kg screen 6 . Stable dosing ( least 3 month ) medication may affect function muscle , nerve and/or neuromuscular transmission gene expression ( include limit : coenzyme Q10 , creatine monohydrate , nutritional supplement , oral salbutamol , valproic acid , sodium phenylbutyrate , hydroxyurea ) 7 . Written inform consent obtain patient and/or parent legal guardian 1 . Clinical presentation and/or genetic test consistent SMA type II III 2 . Inability unwillingness swallow celecoxib suspension 3 . Major surgery ( scoliosis repair , Gtube insertion ) within past 3 month 4 . Known hypersensitivity allergy celecoxib ( include asthma , urticaria and/or allergic symptom result prior celecoxib ingestion ) excipients , NSAIDs ( nonsteroidal antiinflammatory drug ) include ASA ( Acetylsalicylic Acid ) 5 . Known hypersensitivity allergy OraBlendÂ® excipients 6 . Demonstrated allergictype reaction sulfonamides 7 . Celecoxib use within 2 week prior screen visit 8 . Known cardiac ( ie . uncontrolled heart failure , cerebrovascular bleeding , hypertension require use antihypertensive medication ) , hepatic ( i.e . severe liver impairment active liver disease ) , gastrointestinal ( i.e . inflammatory bowel disease ; active gastric/duodenal/peptic ulcer disease ; active gastrointestinal bleeding ) , hematologic ( ie . thrombocytopenia define platelet &lt; 50,000 hemophilia ) , respiratory renal disease ( i.e . severe renal impairment define creatinine clearance &lt; 30 mL/min ) wherein use NSAIDs contraindicate per Product Monograph date 03 March 2015 . 9 . Concurrent use medication contraindicate Celecoxib use ( include limit , warfarin , fluconazole , lithium , hydrochlorothiazide ) 10 . Female pregnant breast feed 11 . Female childbearing potential sexually active unwilling unable use least one form highly effective one effective method birth control . 12 . Patients participate pharmaceutical clinical trial ( active agent ) could impact result study 13 . Inability refusal provide inform consent</criteria>
	<gender>All</gender>
	<minimum_age>2 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>September 2016</verification_date>
</DOC>